V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220013976 | 220017959 | 1.84 | 85.7 | null | 2018-05-06 | 2018-05-06 | FLAG | N | N | 220031949 | FLAG |
| 220013977 | 220008422 | null | 84 | Curative (C) | 2014-11-19 | 2014-11-19 | Triple / Double Intrathecal Therapy | null | null | 220031952 | TRIPLE INTRATHECAL |
| 220013978 | 220008424 | 1.95 | 22.6 | Curative (C) | 2014-12-02 | 2014-12-02 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031953 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013979 | 220014564 | null | null | Curative (C) | 2013-06-16 | 2013-08-11 | ATG + Busulfan + Fludarabine | N | N | 220031962 | ATG + BUSULFAN + FLUDARABINE |
| 220013980 | 220014564 | 1.59 | 60.3 | Palliative (P) | 2014-10-11 | 2014-10-11 | Triple Intrathecal | 02 | N | 220031962 | TRIPLE INTRATHECAL |
| 220013981 | 220021909 | 1.85 | 64 | Palliative (P) | 2016-02-21 | 2016-02-22 | BOSUTINIB | 02 | N | 220031969 | BOSUTINIB |
| 220013982 | 220022105 | 1.67 | 0 | Curative (C) | 2014-05-03 | 2014-05-03 | ATG + Busulfan + Fludarabine | N | N | 220031971 | ATG + BUSULFAN + FLUDARABINE |
| 220013983 | 220022105 | 1.57 | 66 | null | 2017-06-04 | 2017-06-14 | Methotrexate intrathecal | Y | null | 220031971 | METHOTREXATE INTRATHECAL |
| 220013984 | 220022105 | 1.52 | 57.4 | Disease modification (D) | 2013-05-10 | 2013-07-06 | Methotrexate intrathecal | Y | N | 220031971 | METHOTREXATE INTRATHECAL |
| 220013985 | 220022105 | 0 | 55 | Disease modification (D) | 2018-01-21 | 2018-01-21 | CYCLOPHOSPHAMIDE + FLUDARABINE | 01 | N | 220031971 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013986 | 220008427 | 1.72 | 115 | Adjuvant (A) | 2014-03-29 | 2014-03-31 | AML Int Guide ADE 10+3+5 (1) | null | null | 220031997 | ADE |
| 220013987 | 220008427 | 0 | 39.7 | Curative (C) | 2015-10-11 | 2015-10-12 | RUXOLITINIB | N | Y | 220031997 | RUXOLITINIB |
| 220013988 | 220008429 | null | 56 | null | null | 2014-02-18 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220032001 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013989 | 220008430 | null | 57 | Disease modification (D) | 2017-07-10 | 2017-07-17 | AML Int Guide ADE 8+3+5 (2) | N | N | 220032004 | ADE |
| 220013990 | 220017963 | 1.65 | 62.3 | Curative (C) | null | 2017-06-17 | AML16 DA 3+10 | null | null | 220032005 | AML16 TRIAL |
| 220013991 | 220017963 | null | 55.8 | Disease modification (D) | 2018-01-05 | 2018-01-05 | BOSUTINIB | N | N | 220032005 | BOSUTINIB |
| 220013993 | 220008433 | 1.67 | 23.6 | Curative (C) | 2014-07-06 | 2014-07-08 | BOSUTINIB | N | N | 220032022 | BOSUTINIB |
| 220013994 | 220008434 | null | 114 | Curative (C) | 2016-05-01 | 2016-07-02 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220032025 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013995 | 220008438 | 0 | 88.5 | Palliative (P) | 2014-08-08 | 2014-10-05 | CYCLOPHOSPHAMIDE + FLUDARABINE | Y | N | 220032027 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220013996 | 220008438 | 1.9 | 93 | Curative (C) | 2015-06-19 | 2015-06-23 | ATG + Busulfan + Fludarabine | Y | N | 220032027 | ATG + BUSULFAN + FLUDARABINE |
| 220013997 | 220008440 | 1.91 | 78 | Disease modification (D) | 2017-04-26 | 2017-05-02 | Triple Intrathecal | null | N | 220032029 | TRIPLE INTRATHECAL |
| 220013998 | 220008440 | 1.85 | 96.7 | Curative (C) | 2016-07-31 | 2016-08-12 | FLAG | N | N | 220032029 | FLAG |
| 220013999 | 220008441 | 1.66 | 65.9 | Curative (C) | 2013-09-11 | 2013-09-11 | BOSUTINIB | 02 | N | 220032036 | BOSUTINIB |
| 220014000 | 220008441 | 1.75 | null | Disease modification (D) | 2016-11-08 | 2016-11-20 | IDARUBICIN + TRETINOIN | N | N | 220032036 | IDARUBICIN + TRETINOIN |
| 220014001 | 220014576 | 1.67 | 68.4 | Curative (C) | 2017-08-12 | 2017-08-24 | RUXOLITINIB | N | N | 220032041 | RUXOLITINIB |
| 220014002 | 220014576 | null | null | Palliative (P) | 2016-01-17 | 2016-03-28 | ATG + Busulfan + Fludarabine | 02 | N | 220032041 | ATG + BUSULFAN + FLUDARABINE |
| 220014003 | 220008445 | 1.7 | 0 | Curative (C) | 2014-11-21 | 2014-11-21 | ATG + Busulfan + Fludarabine | N | N | 220032050 | ATG + BUSULFAN + FLUDARABINE |
| 220014004 | 220008448 | 1.68 | 50.6 | Curative (C) | 2017-06-19 | 2017-06-26 | Cyclophosphamide TBI Allograft | 2 | N | 220032050 | CYCLOPHOSPHAMIDE |
| 220014005 | 220008450 | 1.59 | 113.8 | Curative (C) | 2014-11-10 | 2014-11-10 | RUXOLITINIB | N | N | 220032056 | RUXOLITINIB |
| 220014006 | 220008452 | null | null | Not known (9) | 2013-01-13 | 2013-03-01 | RUXOLITINIB | 99 | N | 220032058 | RUXOLITINIB |
| 220014007 | 220008453 | null | 60.9 | Not known (9) | 2018-01-15 | 2018-01-15 | ATG + Busulfan + Fludarabine | N | N | 220032061 | ATG + BUSULFAN + FLUDARABINE |
| 220014008 | 220008453 | 1.87 | 87.8 | Curative (C) | 2014-04-30 | 2014-05-14 | BOSUTINIB | 02 | N | 220032061 | BOSUTINIB |
| 220014009 | 220008456 | 1.74 | 79.4 | Not known (9) | null | 2017-10-10 | FLAG | N | N | 220032064 | FLAG |
| 220014010 | 220008457 | 1.59 | 0 | Disease modification (D) | 2014-10-04 | 2014-11-01 | Triple Intrathecal | N | N | 220032067 | TRIPLE INTRATHECAL |
| 220014011 | 220008458 | null | 20 | Curative (C) | 2017-04-03 | 2017-04-03 | RUXOLITINIB | 2 | N | 220032067 | RUXOLITINIB |
| 220014012 | 220014583 | 1.83 | null | null | 2015-08-09 | 2015-08-13 | IDARUBICIN + TRETINOIN | N | N | 220032072 | IDARUBICIN + TRETINOIN |
| 220014013 | 220008462 | 1.8 | 56.2 | Curative (C) | 2015-12-11 | 2015-12-11 | BOSUTINIB | N | N | 220032087 | BOSUTINIB |
| 220014014 | 220008464 | 1.96 | 60 | Curative (C) | 2016-10-03 | 2017-02-13 | BOSUTINIB | N | N | 220032087 | BOSUTINIB |
| 220014015 | 220008465 | null | 94 | Curative (C) | 2016-03-04 | 2016-03-04 | AML16 DA 2+5 | 02 | N | 220032105 | AML16 TRIAL |
| 220014016 | 220014588 | 1.79 | null | Curative (C) | 2013-04-16 | 2013-04-16 | AML16 Low Dose Cytarabine | 02 | N | 220032108 | AML16 TRIAL |
| 220014018 | 220014590 | null | 66.2 | Curative (C) | 2014-01-19 | 2014-01-25 | Triple / Double Intrathecal Therapy | 02 | null | 220032113 | TRIPLE INTRATHECAL |
| 220014019 | 220008481 | null | 74 | Curative (C) | 2016-03-09 | 2016-03-21 | AML Int Guide ADE 8+3+5 (2) | N | N | 220032113 | ADE |
| 220014020 | 220008481 | 1.74 | 71.8 | Curative (C) | 2017-08-04 | 2017-08-04 | RUXOLITINIB | null | null | 220032113 | RUXOLITINIB |
| 220014021 | 220008482 | null | 95 | Curative (C) | 2014-05-29 | 2014-08-22 | Idarubicin+Tretinoin Spanish Crse4 | null | null | 220032121 | IDARUBICIN + TRETINOIN |
| 220014022 | 220019869 | 0 | null | Curative (C) | 2013-10-18 | 2013-10-18 | FLAG | 2 | N | 220032125 | FLAG |
| 220014023 | 220008484 | 1.63 | 77.4 | Disease modification (D) | 2013-11-15 | 2013-11-15 | CYCLOPHOSPHAMIDE | 2 | N | 220032126 | CYCLOPHOSPHAMIDE |
| 220014024 | 220008486 | 1.69 | 10.6 | Curative (C) | 2015-04-14 | 2015-04-14 | FLAG | N | N | 220032131 | FLAG |
| 220014025 | 220008486 | 1.7 | 46.9 | Not known (9) | 2017-03-03 | 2017-03-04 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 220032131 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014026 | 220008487 | 1.41 | null | Curative (C) | 2017-06-27 | 2017-08-03 | Methotrexate intrathecal | null | null | 220032142 | METHOTREXATE INTRATHECAL |
| 220014027 | 220014595 | null | 56.7 | Curative (C) | 2013-12-09 | 2013-12-09 | AML16 DA 3+10 | null | null | 220032142 | AML16 TRIAL |